Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | F12 | P00748 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28507681 | 0.74 | KDM4E (0.47) | ALDH1A1KDM4ETSHRSMN1; SMN2MEN1 | |
| SCHEMBL28668509 | 0.74 | ENPP2 (0.38) | ALDH1A1KDM4EENPP2SMN1; SMN2MEN1 | |
| SCHEMBL1404632 | 0.74 | ENPP2 (0.38) | ALDH1A1KDM4EENPP2TSHRPLG | |
| SCHEMBL29954387 | 0.73 | KMO (0.34) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL1843516 | 0.73 | KMO (0.34) | ALDH1A1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL29952078 | 0.73 | UHRF1 (0.50) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL1843835 | 0.73 | UHRF1 (0.50) | ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL4484450 | 0.73 | NR4A2 (0.38) | ALDH1A1ENPP2MAPTSMN1; SMN2LMNA | |
| SCHEMBL2814691 | 0.70 | NUDT1 (0.30) | ASIC3 | |
| SCHEMBL29806893 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116178337-B | Benzodiazepine compounds and their use as Rho kinase inhibitors | 成都奥睿药业有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4527393-A1 | SURFACE-MODIFIED NANODIAMOND | Kyoto University (JP) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023223962-A1 | SURFACE-MODIFIED NANODIAMOND | 国立大学法人京都大学 | 2023-11-23 | — | — | WO | disclosed |
| WO-2023093787-A1 | BENZODIAZEPINE COMPOUND AND APPLICATION THEREOF AS RHO KINASE INHIBITOR | 成都奥睿药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| CN-116178337-A | Benzodiazepine compounds and their use as Rho kinase inhibitors | 成都奥睿药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2925319-B1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | UNIV ROCHESTER (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3037421-A1 | MLK INHIBITORS AND METHODS OF USE | University Of Rochester (US) | 2016-06-29 | — | — | EP | disclosed |
| EP-2379561-B1 | MLK INHIBITORS AND METHODS OF USE | UNIV ROCHESTER (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150297587-A1 | MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES | MLKL, MARCKS, MAP3K4 | ASIC3 4295/4885ALDH1A1 4296/4885KDM4E 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.